Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Hosted on MSN12h
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDAIt was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback